Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?
Article first published online: 6 OCT 2013
Published 2013. This article is a U.S. Government work and is in the public domain in the USA.
Journal of Viral Hepatitis
Volume 21, Issue 1, pages 1–8, January 2014
How to Cite
Cheng, F.-K. F., Torres, D. M. and Harrison, S. A. (2014), Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy?. Journal of Viral Hepatitis, 21: 1–8. doi: 10.1111/jvh.12172
- Issue published online: 12 DEC 2013
- Article first published online: 6 OCT 2013
- hepatitis C;
- lipid metabolism;
Chronic hepatitis C (CHC) and nonalcoholic fatty liver disease (NAFLD) have an individual prevalence of 1.8–3% and at least 30%, respectively, in the United States. It is therefore not surprising that there is overlap between these two common chronic liver diseases, although the relationship appears to go beyond isolated co-existence. Hepatic steatosis is a common feature of CHC infection and can be related to both metabolic and viral specific factors. Steatosis in the setting of nongenotype 3 CHC has been predictive of response to therapy prior to the advent of the direct acting antiviral medications (DAAs). Similarly, lipid metabolism appears important in response to CHC treatment. The pathways for both lipid homeostasis and NAFLD as it pertains to CHC infection as well as the utilization of statin therapy in CHC infection will be reviewed with a focus on the relevance of these topics in the era of DAA therapy.